Warning Letter — Wild Arabic Herbs
The FDA issued a warning letter to Wild Arabic Herbs on June 17, 2026, following an evaluation by the Center for Drug Evaluation and Research (CDER).
This affects Wild Arabic Herbs, as well as regulatory and compliance departments within firms marketing herbal or botanical products that may be subject to CDER oversight.
The involvement of CDER suggests that the products in question were likely being marketed with therapeutic claims that classify them as unapproved new drugs rather than dietary supplements. This action underscores the FDA's continued scrutiny of herbal product marketing and the potential for such products to be regulated under drug authorities if health claims are present.
Review all product labeling and website claims to ensure no unauthorized therapeutic claims are being made. Verify that products marketed as herbal supplements do not meet the statutory definition of a drug through intended use marketing. Ensure rigorous oversight of digital marketing materials for compliance with CDER standards.
FDA Warning Letter issued to: Wild Arabic Herbs. 06/17/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wild-arabic-herbs-729192-06172026
Open in openFDA / FDA.gov